The global interventional oncology market size is anticipated to reach USD 4.38 billion by 2030 and is expected to expand at a CAGR of 8.55% during the forecast period, according to a new report by Grand View Research, Inc. The rising global burden of cancer, which continues to drive demand for more effective and less invasive treatment modalities. 

Interventional oncology offers targeted therapies such as radiofrequency ablation, cryoablation, and transarterial chemoembolization, which are increasingly preferred over conventional surgical and chemotherapeutic approaches due to their reduced systemic toxicity, shorter recovery times, and lower complication rates. As cancer incidence escalates—particularly in liver, lung, and kidney malignancies—these minimally invasive procedures are gaining traction among healthcare providers and patients alike.

Technological advancements have further accelerated the adoption of interventional oncology techniques. Innovations in imaging modalities, catheter design, and ablation technologies have enhanced the precision and safety of these procedures, making them more accessible and effective. The integration of image-guided interventions allows for real-time monitoring and improved targeting of tumors, thereby optimizing therapeutic outcomes. Additionally, the growing preference for outpatient and day-care procedures, driven by cost-effectiveness and convenience, has bolstered the market’s expansion, especially in regions with strained healthcare infrastructure.

Demographic shifts also play a critical role in shaping market dynamics. The aging global population, coupled with lifestyle-related risk factors such as tobacco use, poor diet, and physical inactivity, has contributed to a surge in cancer diagnoses. This demographic trend necessitates scalable and patient-friendly treatment options, which interventional oncology is well-positioned to provide. Moreover, increasing public and private investments in oncology research and heightened awareness of early cancer detection and treatment are expected to sustain the market’s momentum over the forecast period.

Order a free sample PDF of the Interventional Oncology Market  Intelligence Study, published by Grand View Research.

Further key findings from the report suggest:

• By technique, the ablation therapies segment dominated the market with the largest revenue share of 37.1% in 2024.

• By procedures, the vascular interventions segment captured the largest revenue share of 38.2% in 2024.

• By applications, the liver cancer segment accounted for the largest revenue share of 28.0% in 2024.

• North America interventional oncology market dominated the global industry and accounted for a revenue share of 41.87% in 2024.

• The interventional oncology market in the U.S. is anticipated to witness lucrative growth over the forecast period.

• In December 2024, AngioDynamics received FDA 510(k) clearance for its NanoKnife System to ablate prostate tissue. This non-thermal, radiation-free technology offers a minimally invasive treatment option for prostate cancer patients.

List of Key Players in the Interventional Oncology Market 

• Medtronic plc

• Boston Scientific Corporation

• Johnson & Johnson (Ethicon)

• Teleflex Incorporated

• Cook Medical

• AngioDynamics Inc.

• Stryker Corporation

• Profound Medical

• Terumo Corporation

• Siemens Healthineers

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.